BLLNBillionToOne, Inc.

Healthcare

$107.73

$64.0352 weeks$149.76

Is the price fair?

Watch

A demanding price: priced for a lot of growth and rich vs its sector.

2 to watch, 1 without data

What the price assumes~+33% a year

Priced for ~33% a year FCF growth. The price already bakes in strong, sustained growth.

Vs sector (EV/EBIT)106.8×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 3% of the market

FCF yieldbottom 2% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What BLLN's price assumes

BillionToOne, Inc. trades at 154× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.

154

Trailing P/E · Diagnostics & Research median 36.7 · 4.19× the median: the market pays up for this one

Price / sales: 12.8
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 0.65%
Free cash flow yield · Diagnostics & Research median 2.9%
Growth the price implies: +33%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.